The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Yep
The team should be arriving at the venue soon.
Surely someone on the board is going to the convention and can give us some feedback?
Be useful to know if there is a buzz around Avacta's poster.
Sure As will be talking about p1a the same as Chris
It's a good question though. Why both?
The boffins are lookimg for efficacy.
Conclusions: AVA6000 delivers high concentration of doxorubicin to the TME relative to plasma which results in antitumor activity in tumors with high FAP activity. A q2w dose escalation arm is ongoing.
I am going by the conclusion as being the most important part. Partly because I don't understand much of the jargon used. The conclusion is very positive.
Definition. This refers to the proportion of patients who, according to internationally recognized criteria for alleviating evaluation, achieve tumor relief (PR+CR) and stable disease (SD) after treatment and can maintain for the minimum duration requirement
Some still maybe on the drug. But unless he has been told this weekend he is going by news in November
Doggy. It's ramping nonsense.
He is taking that from the note in November last year. We are 7 months on now.
And also lack of buzz around the company.
A lot of trust has gone from the CEO'S talk. I suspect investors want to see tangible progress from Avacta.
Mr Smith also needs to be clear and upfront about timelines
Do you guys seriously thing Mr Smith is using AI?
I think it would be beneficial if AS adopts an American accent for the presentation and q and a. Avacta really need to concentrate on the US market.
So, Avacta have dumped investormeetscompany?
Katie pilbeam moderating the q and a
https://www.katiepilbeam.com/
Yep, do get the impression it's one individual that has become obsessed
What are you up expecting Mr Smith to say?
It's all in the RNS's.
Totally agree. Like it or not the outstanding Science (or company) is on the AIM market. And that brings with it a wild west reputation.
What's needed is a some savvy leadership to navigate. And I'm not convinced Avacta has that. Not saying the science won't prevail. But going by past experiences I would vote for a new CEO.
Moniman, that is one of the most stupid posts I've read on this forum. Amd that takes some doing.
Or to put it another way. If the share price remains at 50 pence when the next instalment is due.
Mr Smith and his trail blazing CEO will be diluting the company by circa 2%!! (7 millions shares) for one quarterly payment.
Happy to be corrected if if I'm misunderstanding.